I don't like this:
Looking to 2022, Astra said revenue at its Covid-19 medicine arm is to decline in the low-to-mid twenties percentage range. Vaccine sales are expected to dwindle, though revenue from its Evusheld Covid antibody treatment will pick up some of the slack.
Any comments on this?